Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
28 mars 2018 08h00 HE
|
Actinium Pharmaceuticals
- Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents - Actinium to perform preclinical...
Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference
15 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 28th...
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
14 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or...
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
13 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah Combination trial expands...
Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference
07 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30th...
Actinium Announces $15.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering
05 mars 2018 07h30 HE
|
Actinium Pharmaceuticals
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) --
Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that the Company’s previously announced rights...
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
28 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...
Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B
27 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Current clinical trial sites represent over one-third of bone marrow transplant volume in the U.S. - Actinium expects continued site additions to support enrollment and trial completion...
Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and Amendment to Pricing Terms of its Rights Offering
26 févr. 2018 09h53 HE
|
Actinium Pharmaceuticals
- Pricing of the units has been amended to $0.50 per unit with corresponding amendments to the warrant exercise prices - Timing of the offering is expected to be unchanged and the subscription...
Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period
22 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Subscription period expected to end on March 2, 2018 at 5:00 PM ET NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"),...